Toronto Dominion Bank
ENGNW icon

Toronto Dominion Bank’s enGene Therapeutics Warrants ENGNW Stock Holding History

Toronto Dominion Bank’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.15K Buy
+31,545
New +$32.8K ﹤0.01% 2105
2025
Q4 		– Sell
-101
Closed -$72 – 2146
2025
Q3 		$72 Hold
101
– – ﹤0.01% 1882
2025
Q2 		$83 Buy
+101
New +$70 ﹤0.01% 1763

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Toronto Dominion Bank's ENGNW Position: Q2 2026 in Review

Toronto Dominion Bank opened a new position in enGene Therapeutics Warrants (ENGNW) in Q2 2026: 31,545 shares worth $9.15K. The stake represents ﹤0.01% of the portfolio and ranks #2105 among its holdings. This is a return to the name: Toronto Dominion Bank previously reported a position in ENGNW as recently as Q3 2025.

Toronto Dominion Bank first reported a position in ENGNW in Q2 2025 and has held it in 3 quarters since. 11 funds tracked by Wall St. Rank hold ENGNW as of Q2 2026.

  • Toronto Dominion Bank held 31,545 shares of enGene Therapeutics Warrants worth $9.15K as of Q2 2026.
  • enGene Therapeutics Warrants was a new Toronto Dominion Bank position in Q2 2026.
  • enGene Therapeutics Warrants made up ﹤0.01% of Toronto Dominion Bank's portfolio in Q2 2026, its #2105 holding.
  • Toronto Dominion Bank first reported a position in enGene Therapeutics Warrants in Q2 2025 and has held it in 3 quarters since.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2026.

Based on Toronto Dominion Bank's 13F filing for Q2 2026, filed 14 Aug 2026.